SRB5
/ SunRock Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 20, 2025
SunRock Biopharma…announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD), with potential expansion into other immune-mediated inflammatory indications
(Businesswire)
- "Through this partnership, SunRock will benefit from Chime Biologics’ global-standard GMP manufacturing platform to scale production and accelerate preclinical and regulatory milestones."
Licensing / partnership • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1